Atria Wealth Solutions Inc. Decreases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Atria Wealth Solutions Inc. trimmed its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 2.7% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,909 shares of the biotechnology company’s stock after selling 300 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in Sarepta Therapeutics were worth $1,724,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SRPT. Principal Securities Inc. acquired a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at $26,000. Mather Group LLC. acquired a new stake in Sarepta Therapeutics in the first quarter valued at $28,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 125 shares in the last quarter. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics in the 1st quarter valued at about $32,000. Finally, GAMMA Investing LLC raised its position in shares of Sarepta Therapeutics by 37.0% during the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on SRPT. Needham & Company LLC reissued a “buy” rating and set a $235.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, June 27th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, August 15th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a research note on Friday, May 17th. Evercore ISI upgraded Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and cut their target price for the stock from $185.00 to $179.00 in a research report on Thursday, August 8th. Finally, Robert W. Baird boosted their target price on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, June 21st. Three analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $186.22.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $141.43 on Friday. The company’s fifty day moving average is $143.21 and its two-hundred day moving average is $132.36. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. The firm has a market capitalization of $13.37 billion, a P/E ratio of 1,285.73 and a beta of 0.89. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period in the prior year, the business posted ($0.27) earnings per share. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. Analysts forecast that Sarepta Therapeutics, Inc. will post 3.76 EPS for the current fiscal year.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the transaction, the director now directly owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were acquired at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the purchase, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $161.61, for a total transaction of $6,295,840.77. Following the completion of the transaction, the executive vice president now owns 17,129 shares in the company, valued at $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.